- Rechallenge with anti-EGFR therapy2023 | Third Faculty of Medicine
- Anti-EGFR therapy in colorectal carcinoma2017 | Publication without faculty affiliation
- Tolerance of the anti-EGFR therapy2012 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Options and rationale for reinstituting anti-EGFR therapy in pretreated RAS wild-type advanced colorectal carcinomas2023 | Publication without faculty affiliation
- Significance of RAS testing in colorectal cancer2015 | First Faculty of Medicine
- Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas2012 | First Faculty of Medicine
- Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas2012 | Publication without faculty affiliation
- KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma2011 | First Faculty of Medicine
- Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach2022 | Publication without faculty affiliation
- Long-term effect of panitumumab therapy in a patient with primarily generalized colorectal cancer - case report2021 | Publication without faculty affiliation
- KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma2011 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Effect of preoperative radiochemotherapy on rectal adenocarcinoma EGFR expression Effect of preoperative radiochemotherapy on rectal adenocarcinoma EGFR expression2012 | Faculty of Medicine in Hradec Králové
- Localization of right/left side of colorectal carcinomas and its importance in prognosis and therapy disease2017 | Third Faculty of Medicine
- Patient with metastatic colorectal cancer treated in the third line of therapy with trifluridin/tipiracil2018 | First Faculty of Medicine
- Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment2016 | Faculty of Medicine in Pilsen
- Efficacy of anti-VEGF therapy with afliberceptem in advanced colorectal cancer2017 | Publication without faculty affiliation
- Efficacy of anti-VEGF therapy (aflibercept) in advanced colorectal cancer2019 | Publication without faculty affiliation
- Cetuximab in metastatic mucinous adenocarcinoma of the colon2016 | First Faculty of Medicine
- Possibilities and substantiation of re-treatment with anti-EGFR drugs for pre-treated RAS wild-type advanced colorectal cancers2021 | Publication without faculty affiliation
- Mechanism of HPV infection associated with head and neck tumors2019 | First Faculty of Medicine, Third Faculty of Medicine
- Anti-EGFR treatment of colorectal cancer2021 | Publication without faculty affiliation
- Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma2012 | Faculty of Medicine in Hradec Králové
- The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line2018 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab2015 | Publication without faculty affiliation
- Regorafenib - role of the drug in the current real-life oncological practice2018 | Publication without faculty affiliation
- Molecular and IHC analysis of head and neck carcinomas associated with HPV infection2019 | First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions2020 | Faculty of Medicine in Pilsen, Second Faculty of Medicine